Recent preclinical studies suggest that inhibitors of histone methyltransferases represent promising drug candidates for cancer therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets
BMC Medical Genetics Open Access 31 December 2018
-
Lysine Possesses the Optimal Chain Length for Histone Lysine Methyltransferase Catalysis
Scientific Reports Open Access 23 November 2017
-
Epigenetic regulation and chromatin remodeling in learning and memory
Experimental & Molecular Medicine Open Access 13 January 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kelly, T.K., De Carvalho, D.D. & Jones, P.A. Nat. Biotechnol. 28, 1069–1078 (2010).
Bissinger, E.M. et al. Med. Chem. Commun. 1, 114–124 (2010).
Vedadi, M. et al. Nat. Chem. Biol. 7, 566–574 (2011).
Yuan, Y. et al. ACS Chem. Biol. advance online publication, doi:10.1021/cb300139y (26 April 2012).
Bernt, K.M. et al. Cancer Cell 20, 66–78 (2011).
Daigle, S.R. et al. Cancer Cell 20, 53–65 (2011).
Ferguson, A.D. et al. Structure 19, 1262–1273 (2011).
Chang, C.J. & Hung, M.C. Br. J. Cancer 106, 243–247 (2012).
Sneeringer, C.J. et al. Proc. Natl. Acad. Sci. USA 107, 20980–20985 (2010).
Morin, R.D. et al. Nat. Genet. 42, 181–185 (2010).
Chase, A. & Cross, N.C.P. Clin. Cancer Res. 17, 2613–2618 (2011).
Zhang, J. et al. Nature 481, 157–163 (2012).
He, M. et al. Cancer Res. advance online publication, doi:10.1158/0008-5472.CAN-11-2876 (16 May 2012).
Burgess, J. et al. Azaindazoles. WO2012/005805 A1 (2012).
Henikoff, S. & Shilatifard, A. Trends Genet. 27, 389–396 (2011).
Willmann, D. et al. Int. J. Cancer Preprint at http://onlinelibrary.wiley.com/doi/10.1002/ijc.27555/abstract (2012).
Schenk, T. et al. Nat. Med. 18, 605–611 (2012).
Acknowledgements
We thank the Deutsche Krebshilfe (Nr. 107898) for funding of our work on histone methyltransferases.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wagner, T., Jung, M. New lysine methyltransferase drug targets in cancer. Nat Biotechnol 30, 622–623 (2012). https://doi.org/10.1038/nbt.2300
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2300
This article is cited by
-
Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma
European Journal of Nutrition (2021)
-
Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling
Acta Pharmacologica Sinica (2019)
-
Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets
BMC Medical Genetics (2018)
-
Lysine Possesses the Optimal Chain Length for Histone Lysine Methyltransferase Catalysis
Scientific Reports (2017)
-
Epigenetic regulation and chromatin remodeling in learning and memory
Experimental & Molecular Medicine (2017)
